. 2014 Dec; 263(1):90-105.
doi: 10.1111/imr.12245.

Novel immunotherapies for hematologic malignancies

Michelle H Nelson 1 Chrystal M Paulos  
  • PMID: 25510273
  •     175 References
  •     21 citations


The immune system is designed to discriminate between self and tumor tissue. Through genetic recombination, there is fundamentally no limit to the number of tumor antigens that immune cells can recognize. Yet, tumors use a variety of immunosuppressive mechanisms to evade immunity. Insight into how the immune system interacts with tumors is expanding rapidly and has accelerated the translation of immunotherapies into medical breakthroughs. Herein, we appraise novel strategies that exploit the patient's immune system to kill cancer. We review various forms of immune-based therapies, which have shown significant promise in patients with hematologic malignancies, including (i) conventional monoclonal therapies like rituximab; (ii) engineered monoclonal antibodies called bispecific T-cell engagers; (iii) monoclonal antibodies and pharmaceutical drugs that block inhibitory T-cell pathways (i.e. PD-1, CTLA-4, and IDO); and (iv) adoptive cell transfer therapy with T cells engineered to express chimeric antigen receptors or T-cell receptors. We also assess the idea of using these therapies in combination and conclude by suggesting multi-prong approaches to improve treatment outcomes and curative responses in patients.

Keywords: adoptive T-cell transfer therapy; allogeneic hematopoietic stem cell transplantation; bispecific T-cell engagers; gene transfer; immune checkpoint modulators; monoclonal antibodies.

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
Chrystal U Louis, Karin Straathof, +12 authors, Stephen Gottschalk.
J Immunother, 2010 Oct 16; 33(9). PMID: 20948438    Free PMC article.
Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.
J Ritz, S F Schlossman.
Blood, 1982 Jan 01; 59(1). PMID: 7032624
Bispecific antibodies engage T cells for antitumor immunotherapy.
Bryan D Choi, Mingqing Cai, +3 authors, John H Sampson.
Expert Opin Biol Ther, 2011 Apr 01; 11(7). PMID: 21449821
Recruiting cytotoxic T cells to folate-receptor-positive cancer cells.
Sumith A Kularatne, Vishal Deshmukh, +15 authors, Peter G Schultz.
Angew Chem Int Ed Engl, 2014 Feb 28; 52(46). PMID: 24573789    Free PMC article.
Adaptive immunity maintains occult cancer in an equilibrium state.
Catherine M Koebel, William Vermi, +5 authors, Robert D Schreiber.
Nature, 2007 Nov 21; 450(7171). PMID: 18026089
Highly Cited.
Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide.
T M Aune, S L Pogue.
J Clin Invest, 1989 Sep 01; 84(3). PMID: 2503544    Free PMC article.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
T-cell immunotherapy: looking forward.
Jacqueline Corrigan-Curay, Hans-Peter Kiem, +23 authors, Donald B Kohn.
Mol Ther, 2014 Sep 05; 22(9). PMID: 25186558    Free PMC article.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
James N Kochenderfer, Wyndham H Wilson, +9 authors, Steven A Rosenberg.
Blood, 2010 Jul 30; 116(20). PMID: 20668228    Free PMC article.
Highly Cited.
Monoclonal antibodies for B-cell lymphomas: rituximab and beyond.
Celeste Bello, Eduardo M Sotomayor.
Hematology Am Soc Hematol Educ Program, 2007 Nov 21;. PMID: 18024635
The path to personalized medicine.
Margaret A Hamburg, Francis S Collins.
N Engl J Med, 2010 Jun 17; 363(4). PMID: 20551152
Highly Cited.
Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice.
J A Titus, M A Garrido, +3 authors, D M Segal.
J Immunol, 1987 Jun 01; 138(11). PMID: 3108382
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.
Maria Stefania De Propris, Sara Raponi, +5 authors, Anna Guarini.
Haematologica, 2011 Jul 28; 96(10). PMID: 21791474    Free PMC article.
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
Catherine Uyttenhove, Luc Pilotte, +5 authors, Benoît J Van den Eynde.
Nat Med, 2003 Sep 23; 9(10). PMID: 14502282
Highly Cited.
Th17 cells in cancer: the ultimate identity crisis.
Stefanie R Bailey, Michelle H Nelson, +3 authors, Chrystal M Paulos.
Front Immunol, 2014 Jul 06; 5. PMID: 24987392    Free PMC article.
Highly Cited. Review.
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells.
Andreas A Hombach, Johannes Heiders, +2 authors, Hinrich Abken.
Oncoimmunology, 2012 Jul 04; 1(4). PMID: 22754764    Free PMC article.
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Kimberly E Beck, Joseph A Blansfield, +12 authors, James C Yang.
J Clin Oncol, 2006 May 20; 24(15). PMID: 16710025    Free PMC article.
Highly Cited.
The promise and potential pitfalls of chimeric antigen receptors.
Michel Sadelain, Renier Brentjens, Isabelle Rivière.
Curr Opin Immunol, 2009 Mar 31; 21(2). PMID: 19327974    Free PMC article.
Highly Cited. Review.
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Junko Matsuzaki, Sacha Gnjatic, +9 authors, Kunle Odunsi.
Proc Natl Acad Sci U S A, 2010 Apr 14; 107(17). PMID: 20385810    Free PMC article.
Highly Cited.
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Torsten Dreier, Patrick A Baeuerle, +8 authors, Ralf C Bargou.
J Immunol, 2003 Apr 19; 170(8). PMID: 12682277
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Ralf Lutterbuese, Tobias Raum, +12 authors, Peter Kufer.
J Immunother, 2009 Apr 04; 32(4). PMID: 19342971
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
Patrick J Hanley, Conrad Russell Young Cruz, +13 authors, Catherine M Bollard.
Blood, 2009 May 16; 114(9). PMID: 19443656    Free PMC article.
Single chain antibody variable regions.
R E Bird, B W Walker.
Trends Biotechnol, 1991 Apr 01; 9(4). PMID: 1367550
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
Hugo F Fernandez, Zhuoxin Sun, +8 authors, Martin S Tallman.
Blood, 2011 Mar 19; 117(20). PMID: 21415269    Free PMC article.
Indoleamine 2,3-dioxygenase and tumor-induced tolerance.
David H Munn, Andrew L Mellor.
J Clin Invest, 2007 May 04; 117(5). PMID: 17476344    Free PMC article.
Highly Cited. Review.
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.
Francesca Fallarino, Ursula Grohmann, +10 authors, Paolo Puccetti.
J Immunol, 2006 May 20; 176(11). PMID: 16709834
Highly Cited.
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nicholas P Restifo, Mark E Dudley, Steven A Rosenberg.
Nat Rev Immunol, 2012 Mar 23; 12(4). PMID: 22437939    Free PMC article.
Highly Cited. Review.
A human memory T cell subset with stem cell-like properties.
Luca Gattinoni, Enrico Lugli, +14 authors, Nicholas P Restifo.
Nat Med, 2011 Sep 20; 17(10). PMID: 21926977    Free PMC article.
Highly Cited.
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Matthias Friedrich, Tobias Raum, +15 authors, Peter Kufer.
Mol Cancer Ther, 2012 Oct 09; 11(12). PMID: 23041545
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
Carmine Carpenito, Michael C Milone, +11 authors, Carl H June.
Proc Natl Acad Sci U S A, 2009 Feb 13; 106(9). PMID: 19211796    Free PMC article.
Highly Cited.
Bispecific antibodies for cancer immunotherapy: Current perspectives.
Dafne Müller, Roland E Kontermann.
BioDrugs, 2010 Mar 05; 24(2). PMID: 20199124
Upregulation of IFN-gamma receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells.
Kari Ann Shirey, Joo-Yong Jung, Gregory S Maeder, Joseph M Carlin.
J Interferon Cytokine Res, 2006 Jan 24; 26(1). PMID: 16426148    Free PMC article.
Tumor and T cell engagement by BiTE.
Dineli Wickramasinghe.
Discov Med, 2013 Oct 09; 16(88). PMID: 24099669
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Scott A Hammond, Ralf Lutterbuese, +8 authors, Peter A Kiener.
Cancer Res, 2007 Apr 19; 67(8). PMID: 17440108
Prevention of allogeneic fetal rejection by tryptophan catabolism.
D H Munn, M Zhou, +5 authors, A L Mellor.
Science, 1998 Aug 26; 281(5380). PMID: 9712583
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
G Gross, T Waks, Z Eshhar.
Proc Natl Acad Sci U S A, 1989 Dec 01; 86(24). PMID: 2513569    Free PMC article.
Highly Cited.
Inhibition of experimental asthma by indoleamine 2,3-dioxygenase.
Tomoko Hayashi, Lucinda Beck, +6 authors, Eyal Raz.
J Clin Invest, 2004 Jul 16; 114(2). PMID: 15254594    Free PMC article.
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Torsten Dreier, Grit Lorenczewski, +7 authors, Patrick A Baeuerle.
Int J Cancer, 2002 Sep 05; 100(6). PMID: 12209608
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
Rong Zeng, Rosanne Spolski, +9 authors, Warren J Leonard.
J Exp Med, 2005 Jan 05; 201(1). PMID: 15630141    Free PMC article.
Highly Cited.
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology.
Antonio Curti, Sara Trabanelli, +2 authors, Roberto M Lemoli.
Blood, 2008 Nov 22; 113(11). PMID: 19023117
Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.
Arnab Ghosh, Amanda M Holland, Marcel R M van den Brink.
Immunol Rev, 2013 Dec 18; 257(1). PMID: 24329800    Free PMC article.
A theory of self-nonself discrimination.
P Bretscher, M Cohn.
Science, 1970 Sep 11; 169(3950). PMID: 4194660
Highly Cited.
Adoptive T cell therapy for cancer in the clinic.
Carl H June.
J Clin Invest, 2007 Jun 06; 117(6). PMID: 17549249    Free PMC article.
Highly Cited. Review.
T cell exhaustion.
E John Wherry.
Nat Immunol, 2011 Jul 09; 12(6). PMID: 21739672
Highly Cited. Review.
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
C A Chambers, M S Kuhns, J G Egen, J P Allison.
Annu Rev Immunol, 2001 Mar 13; 19. PMID: 11244047
Highly Cited. Review.
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
Ann M Leen, Anne Christin, +11 authors, Catherine M Bollard.
Blood, 2009 Aug 25; 114(19). PMID: 19700662    Free PMC article.
Highly Cited.
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Rikke B Holmgaard, Dmitriy Zamarin, +2 authors, James P Allison.
J Exp Med, 2013 Jun 12; 210(7). PMID: 23752227    Free PMC article.
Highly Cited.
Type 17 CD8+ T cells display enhanced antitumor immunity.
Christian S Hinrichs, Andrew Kaiser, +7 authors, Nicholas P Restifo.
Blood, 2009 May 28; 114(3). PMID: 19471017    Free PMC article.
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Steven A Rosenberg, James C Yang, +12 authors, Mark E Dudley.
Clin Cancer Res, 2011 Apr 19; 17(13). PMID: 21498393    Free PMC article.
Highly Cited.
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Bryan D Choi, Chien-Tsun Kuan, +7 authors, John H Sampson.
Proc Natl Acad Sci U S A, 2012 Dec 19; 110(1). PMID: 23248284    Free PMC article.
Antileukemic effect of interleukin-7-transduced bone marrow stromal cells in mice following allogeneic T-cell-depleted bone marrow transplantation.
A L Li, C Li, +5 authors, S S Xie.
Transplant Proc, 2005 Jun 21; 37(5). PMID: 15964403
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
Richard V Parry, Jens M Chemnitz, +6 authors, James L Riley.
Mol Cell Biol, 2005 Oct 18; 25(21). PMID: 16227604    Free PMC article.
Highly Cited.
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Julien Fourcade, Zhaojun Sun, +6 authors, Hassane M Zarour.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819923    Free PMC article.
Highly Cited.
Induced pluripotent stem cells in hematology: current and future applications.
D Focosi, G Amabile, +3 authors, M Pistello.
Blood Cancer J, 2014 May 13; 4. PMID: 24813079    Free PMC article.
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug.
Jacob M Rowe, Bob Löwenberg.
Blood, 2013 Apr 18; 121(24). PMID: 23591788
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Nam H Dang, Fredrick B Hagemeister, +13 authors, Luis Fayad.
J Clin Oncol, 2004 Sep 09; 22(20). PMID: 15353540
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Patrick Hoffmann, Robert Hofmeister, +6 authors, Patrick A Baeuerle.
Int J Cancer, 2005 Feb 03; 115(1). PMID: 15688411
Changes in serum tryptophan catabolism as an indicator of disease activity in adult T-cell leukemia/lymphoma.
Masato Hoshi, Hiroyasu Ito, +8 authors, Mitsuru Seishima.
Leuk Lymphoma, 2009 Jun 23; 50(8). PMID: 19544139
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
James N Kochenderfer, Mark E Dudley, +15 authors, Steven A Rosenberg.
Blood, 2011 Dec 14; 119(12). PMID: 22160384    Free PMC article.
Highly Cited.
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
Renier J Brentjens, Marco L Davila, +22 authors, Michel Sadelain.
Sci Transl Med, 2013 Mar 22; 5(177). PMID: 23515080    Free PMC article.
Highly Cited.
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
A Löffler, P Kufer, +6 authors, R C Bargou.
Blood, 2000 Mar 09; 95(6). PMID: 10706880
Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.
Amir A Al-Khami, Shikhar Mehrotra, Michael I Nishimura.
Self Nonself, 2012 Feb 03; 2(2). PMID: 22299059    Free PMC article.
Hybrid antibodies can target sites for attack by T cells.
U D Staerz, O Kanagawa, M J Bevan.
Nature, 1985 Apr 18; 314(6012). PMID: 2859527
Highly Cited.
Graft-versus-leukemia reactions in allogeneic chimeras.
Hans-Jochem Kolb, Christoph Schmid, A John Barrett, Dolores J Schendel.
Blood, 2003 Sep 06; 103(3). PMID: 12958064
CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.
M Azuma, M Cayabyab, +2 authors, L L Lanier.
J Exp Med, 1992 Feb 01; 175(2). PMID: 1370679    Free PMC article.
Highly Cited.
Advances in the assessment and control of the effector functions of therapeutic antibodies.
Xu-Rong Jiang, An Song, +7 authors, Mark Schenerman.
Nat Rev Drug Discov, 2011 Feb 02; 10(2). PMID: 21283105
Highly Cited. Review.
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
James N Kochenderfer, Steven A Rosenberg.
Nat Rev Clin Oncol, 2013 Apr 03; 10(5). PMID: 23546520    Free PMC article.
Highly Cited. Review.
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Jedd D Wolchok, F Stephen Hodi, +9 authors, Alan J Korman.
Ann N Y Acad Sci, 2013 Jun 19; 1291. PMID: 23772560    Free PMC article.
Highly Cited. Review.
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
David H Munn, Madhav D Sharma, +7 authors, Andrew L Mellor.
J Clin Invest, 2004 Jul 16; 114(2). PMID: 15254595    Free PMC article.
Highly Cited.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A Grupp, Michael Kalos, +10 authors, Carl H June.
N Engl J Med, 2013 Mar 27; 368(16). PMID: 23527958    Free PMC article.
Highly Cited.
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.
Martine E D Chamuleau, Arjan A van de Loosdrecht, +6 authors, Gert J Ossenkoppele.
Haematologica, 2008 Dec 04; 93(12). PMID: 19050070
Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.
Purevdorj B Olkhanud, Bazarragchaa Damdinsuren, +6 authors, Arya Biragyn.
Cancer Res, 2011 Mar 30; 71(10). PMID: 21444674    Free PMC article.
Highly Cited.
Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).
H Hagberg, M Pettersson, T Bjerner, G Enblad.
Med Oncol, 2005 Jun 21; 22(2). PMID: 15965283
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Bernd Schlereth, Cornelia Quadt, +11 authors, Patrick A Baeuerle.
Cancer Immunol Immunother, 2005 Jul 21; 55(5). PMID: 16032400
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Steven A Rosenberg, Nicholas P Restifo, +2 authors, Mark E Dudley.
Nat Rev Cancer, 2008 Mar 21; 8(4). PMID: 18354418    Free PMC article.
Highly Cited. Review.
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
David L Porter, Bruce L Levine, +2 authors, Carl H June.
N Engl J Med, 2011 Aug 13; 365(8). PMID: 21830940    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G Till, Michael C Jensen, +13 authors, Oliver W Press.
Blood, 2008 May 30; 112(6). PMID: 18509084    Free PMC article.
Highly Cited.
Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
Chrystal M Paulos, Megan M Suhoski, +10 authors, Carl H June.
Immunol Res, 2008 Oct 25; 42(1-3). PMID: 18949448    Free PMC article.
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Asad Bashey, Bridget Medina, +11 authors, Edward D Ball.
Blood, 2008 Nov 01; 113(7). PMID: 18974373    Free PMC article.
Highly Cited.
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
Sonja Offner, Robert Hofmeister, +2 authors, Patrick A Baeuerle.
Mol Immunol, 2005 Dec 20; 43(6). PMID: 16360021
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
Margaret K Callahan, Jedd D Wolchok, James P Allison.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074063    Free PMC article.
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Paul A Antony, Ciriaco A Piccirillo, +9 authors, Nicholas P Restifo.
J Immunol, 2005 Feb 25; 174(5). PMID: 15728465    Free PMC article.
Highly Cited.
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Gregory L Beatty, Elena G Chiorean, +10 authors, Robert H Vonderheide.
Science, 2011 Mar 26; 331(6024). PMID: 21436454    Free PMC article.
Highly Cited.
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
Cornelia Haas, Eva Krinner, +5 authors, Patrick A Baeuerle.
Immunobiology, 2009 Jan 23; 214(6). PMID: 19157637
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Cor H J Lamers, Stefan Sleijfer, +6 authors, Egbert Oosterwijk.
J Clin Oncol, 2006 May 02; 24(13). PMID: 16648493
Highly Cited.
4-1BB-mediated immunotherapy of rheumatoid arthritis.
Su K Seo, Jae H Choi, +6 authors, Byoung S Kwon.
Nat Med, 2004 Sep 28; 10(10). PMID: 15448685
Highly Cited.
"Diabodies": small bivalent and bispecific antibody fragments.
P Holliger, T Prospero, G Winter.
Proc Natl Acad Sci U S A, 1993 Jul 15; 90(14). PMID: 8341653    Free PMC article.
Highly Cited.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E A Tivol, F Borriello, +3 authors, A H Sharpe.
Immunity, 1995 Nov 01; 3(5). PMID: 7584144
Highly Cited.
Retargeting of human regulatory T cells by single-chain bispecific antibodies.
Stefanie Koristka, Marc Cartellieri, +11 authors, Michael Bachmann.
J Immunol, 2011 Dec 21; 188(3). PMID: 22184723
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Dual targeting strategies with bispecific antibodies.
Roland E Kontermann.
MAbs, 2012 Mar 29; 4(2). PMID: 22453100    Free PMC article.
Highly Cited. Review.
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
Michael R Robinson, Chi-Chao Chan, +5 authors, Steven A Rosenberg.
J Immunother, 2004 Nov 10; 27(6). PMID: 15534492
Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
Hitoe Torisu-Itakura, Hans F Schoellhammer, +5 authors, Donald L Morton.
J Immunother, 2011 Sep 10; 34(8). PMID: 21904216    Free PMC article.
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
D G Maloney, A J Grillo-López, +11 authors, R Levy.
Blood, 1997 Oct 06; 90(6). PMID: 9310469
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
John Maher, Renier J Brentjens, +2 authors, Michel Sadelain.
Nat Biotechnol, 2001 Dec 26; 20(1). PMID: 11753365
Highly Cited.
Engineering T cells for cancer: our synthetic future.
Robert H Vonderheide, Carl H June.
Immunol Rev, 2013 Dec 18; 257(1). PMID: 24329786    Free PMC article.
Adoptive immunotherapy for cancer or viruses.
Marcela V Maus, Joseph A Fraietta, +3 authors, Carl H June.
Annu Rev Immunol, 2014 Jan 16; 32. PMID: 24423116    Free PMC article.
Highly Cited. Review.
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Ralf Bargou, Eugen Leo, +17 authors, Peter Kufer.
Science, 2008 Aug 16; 321(5891). PMID: 18703743
Highly Cited.
Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
Roland B Walter.
Expert Rev Hematol, 2014 Mar 13; 7(3). PMID: 24617311
Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.
S Miescher, T L Whiteside, S Carrel, V von Fliedner.
J Immunol, 1986 Mar 01; 136(5). PMID: 2936812
Highly Cited.
Monoclonal antibody therapy for cancer.
Margaret von Mehren, Gregory P Adams, Louis M Weiner.
Annu Rev Med, 2003 Jan 15; 54. PMID: 12525678
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.
Chrystal M Paulos, Carmine Carpenito, +6 authors, Carl H June.
Sci Transl Med, 2010 Oct 29; 2(55). PMID: 20980695    Free PMC article.
Highly Cited.
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Guifang Cai, Gordon J Freeman.
Immunol Rev, 2009 May 12; 229(1). PMID: 19426226
Highly Cited. Review.
Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling.
Andrew L Mellor, Babak Baban, +3 authors, David H Munn.
J Immunol, 2005 Oct 21; 175(9). PMID: 16237046
Highly Cited.
Allogeneic transplantation for lymphoma: long-term outcome.
Paolo Corradini, Lucia Farina.
Curr Opin Hematol, 2010 Aug 19; 17(6). PMID: 20717024
PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
S M Kipriyanov, G Moldenhauer, G Strauss, M Little.
Int J Cancer, 1998 Aug 04; 77(5). PMID: 9688311
Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.
Derek A Wainwright, Maciej S Lesniak.
Oncoimmunology, 2014 Jul 25; 3. PMID: 25057450    Free PMC article.
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
Chrystal M Paulos, Carl H June.
J Clin Invest, 2009 Dec 30; 120(1). PMID: 20038807    Free PMC article.
Immunotherapy of human cancers using gene modified T lymphocytes.
Juan F Vera, Malcolm K Brenner, Gianpietro Dotti.
Curr Gene Ther, 2009 Oct 29; 9(5). PMID: 19860654    Free PMC article.
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
Mary Jo Turk, José A Guevara-Patiño, +3 authors, Alan N Houghton.
J Exp Med, 2004 Sep 24; 200(6). PMID: 15381730    Free PMC article.
Highly Cited.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Mark E Dudley, John R Wunderlich, +18 authors, Steven A Rosenberg.
J Clin Oncol, 2005 Apr 01; 23(10). PMID: 15800326    Free PMC article.
Highly Cited.
Indoleamine 2,3-dioxygenase activity and expression in patients with chronic lymphocytic leukemia.
Vesa Lindström, Janne Aittoniemi, +6 authors, Marjatta Sinisalo.
Clin Lymphoma Myeloma Leuk, 2012 Sep 18; 12(5). PMID: 22981691
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Michael H Kershaw, Jennifer A Westwood, +11 authors, Patrick Hwu.
Clin Cancer Res, 2006 Oct 26; 12(20 Pt 1). PMID: 17062687    Free PMC article.
Highly Cited.
Therapeutic antibodies: successes, limitations and hopes for the future.
Patrick Chames, Marc Van Regenmortel, Etienne Weiss, Daniel Baty.
Br J Pharmacol, 2009 May 23; 157(2). PMID: 19459844    Free PMC article.
Highly Cited. Review.
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Michael C Milone, Jonathan D Fish, +11 authors, Carl H June.
Mol Ther, 2009 Apr 23; 17(8). PMID: 19384291    Free PMC article.
Highly Cited.
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.
Stefan Lob, Alfred Konigsrainer, +3 authors, Peter Terness.
Blood, 2007 Nov 30; 111(4). PMID: 18045970
Monoclonal antibodies: versatile platforms for cancer immunotherapy.
Louis M Weiner, Rishi Surana, Shangzi Wang.
Nat Rev Immunol, 2010 Apr 24; 10(5). PMID: 20414205    Free PMC article.
Highly Cited. Review.
CARs on track in the clinic.
Donald B Kohn, Gianpietro Dotti, +7 authors, Helen E Heslop.
Mol Ther, 2011 Mar 02; 19(3). PMID: 21358705    Free PMC article.
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.
Rikke Baek Sørensen, Sine Reker Hadrup, +3 authors, Mads Hald Andersen.
Blood, 2010 Nov 17; 117(7). PMID: 21079151    Free PMC article.
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.
Lieping Chen.
Nat Rev Immunol, 2004 May 04; 4(5). PMID: 15122199
Highly Cited. Review.
An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.
Pengfei Zhang, Bizhi Shi, +11 authors, Zonghai Li.
Cancer Immunol Immunother, 2013 Nov 02; 63(2). PMID: 24177984
Tumor-specific Th17-polarized cells eradicate large established melanoma.
Pawel Muranski, Andrea Boni, +14 authors, Nicholas P Restifo.
Blood, 2008 Mar 21; 112(2). PMID: 18354038    Free PMC article.
Highly Cited.
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
Bipulendu Jena, Gianpietro Dotti, Laurence J N Cooper.
Blood, 2010 May 05; 116(7). PMID: 20439624    Free PMC article.
Highly Cited. Review.
Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
G J Weiner, J R Hillstrom.
J Immunol, 1991 Dec 01; 147(11). PMID: 1834746
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Christopher A Klebanoff, Luca Gattinoni, +9 authors, Nicholas P Restifo.
Proc Natl Acad Sci U S A, 2005 Jun 28; 102(27). PMID: 15980149    Free PMC article.
Highly Cited.
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
John D Hainsworth, Sharlene Litchy, +5 authors, Minnie Pearl Cancer Research Network.
J Clin Oncol, 2003 May 02; 21(9). PMID: 12721250
An overview of targeted treatments in cancer.
Rony Abou-Jawde, Toni Choueiri, Carlos Alemany, Tarek Mekhail.
Clin Ther, 2003 Sep 27; 25(8). PMID: 14512124
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
James N Kochenderfer, Mark E Dudley, +23 authors, Steven A Rosenberg.
J Clin Oncol, 2014 Aug 27; 33(6). PMID: 25154820    Free PMC article.
Highly Cited.
Antibody-based immunotherapy of cancer.
Louis M Weiner, Joseph C Murray, Casey W Shuptrine.
Cell, 2012 Mar 20; 148(6). PMID: 22424219    Free PMC article.
Rituximab in the treatment of non-Hodgkin's lymphoma.
Beate Hauptrock, Georg Hess.
Biologics, 2009 Aug 27; 2(4). PMID: 19707443    Free PMC article.
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.
Karen S Sfanos, Tullia C Bruno, +3 authors, Charles G Drake.
Prostate, 2009 Aug 12; 69(15). PMID: 19670224    Free PMC article.
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Christopher A Klebanoff, Steven E Finkelstein, +11 authors, Nicholas P Restifo.
Proc Natl Acad Sci U S A, 2004 Feb 06; 101(7). PMID: 14762166    Free PMC article.
Highly Cited.
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Ralf Lutterbuese, Tobias Raum, +13 authors, Peter Kufer.
Proc Natl Acad Sci U S A, 2010 Jul 10; 107(28). PMID: 20616015    Free PMC article.
Breakthrough of the year 2013. Cancer immunotherapy.
Jennifer Couzin-Frankel.
Science, 2013 Dec 21; 342(6165). PMID: 24357284
Highly Cited.
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
Ann M Leen, G Doug Myers, +12 authors, Catherine M Bollard.
Nat Med, 2006 Sep 26; 12(10). PMID: 16998485
Highly Cited.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Peter Attia, Giao Q Phan, +14 authors, Steven A Rosenberg.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087944    Free PMC article.
Highly Cited.
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Jeffrey Weber.
Oncologist, 2007 Aug 04; 12(7). PMID: 17673617
Continuous cultures of fused cells secreting antibody of predefined specificity.
G Köhler, C Milstein.
Nature, 1975 Aug 07; 256(5517). PMID: 1172191
Highly Cited.
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.
Natalia Martin-Orozco, Yufeng Li, +5 authors, Laszlo Radvanyi.
Cancer Res, 2010 Nov 26; 70(23). PMID: 21098714    Free PMC article.
Toll-like receptors in tumor immunotherapy.
Chrystal M Paulos, Andrew Kaiser, +11 authors, Nicholas P Restifo.
Clin Cancer Res, 2007 Sep 19; 13(18 Pt 1). PMID: 17875756    Free PMC article.
Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
M Mack, R Gruber, +2 authors, P Kufer.
J Immunol, 1997 Apr 15; 158(8). PMID: 9103467
Combination checkpoint blockade--taking melanoma immunotherapy to the next level.
James L Riley.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724866
Immunobiology of allogeneic hematopoietic stem cell transplantation.
Lisbeth A Welniak, Bruce R Blazar, William J Murphy.
Annu Rev Immunol, 2006 Nov 30; 25. PMID: 17129175
Highly Cited. Review.
Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
C Renner, W Jung, +7 authors, M Pfreundschuh.
Science, 1994 May 06; 264(5160). PMID: 8171337
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Xiangdong Liu, Niu Shin, +19 authors, Peggy A Scherle.
Blood, 2010 Mar 04; 115(17). PMID: 20197554
Highly Cited.
EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
Michele Cioffi, Jorge Dorado, Patrick A Baeuerle, Christopher Heeschen.
Clin Cancer Res, 2011 Nov 19; 18(2). PMID: 22096026
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
Michael Kalos, Bruce L Levine, +4 authors, Carl H June.
Sci Transl Med, 2011 Aug 13; 3(95). PMID: 21832238    Free PMC article.
Highly Cited.
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
David E Gilham, Reno Debets, +2 authors, Hinrich Abken.
Trends Mol Med, 2012 May 23; 18(7). PMID: 22613370
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Maria Amann, Sandrine D'Argouges, +13 authors, Matthias Friedrich.
J Immunother, 2009 Jul 18; 32(5). PMID: 19609237
Reduced mortality after allogeneic hematopoietic-cell transplantation.
Ted A Gooley, Jason W Chien, +9 authors, George B McDonald.
N Engl J Med, 2010 Nov 26; 363(22). PMID: 21105791    Free PMC article.
Highly Cited.
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
Ann M Leen, Catherine M Bollard, +13 authors, Helen E Heslop.
Blood, 2013 Apr 24; 121(26). PMID: 23610374    Free PMC article.
Highly Cited.
Th17 cells are long lived and retain a stem cell-like molecular signature.
Pawel Muranski, Zachary A Borman, +19 authors, Nicholas P Restifo.
Immunity, 2011 Dec 20; 35(6). PMID: 22177921    Free PMC article.
Highly Cited.
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
Patrick Chames, Daniel Baty.
MAbs, 2010 Jan 16; 1(6). PMID: 20073127    Free PMC article.
Highly Cited. Review.
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Sonia Guedan, Xi Chen, +9 authors, Carl H June.
Blood, 2014 Jul 06; 124(7). PMID: 24986688    Free PMC article.
Highly Cited.
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.
Bryan D Choi, Patrick C Gedeon, +2 authors, John H Sampson.
Oncoimmunology, 2014 Jan 30; 2(12). PMID: 24475376    Free PMC article.
Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.
Ren Lin, Qifa Liu.
J Hematol Oncol, 2013 Dec 18; 6. PMID: 24341630    Free PMC article.
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.
R Handgretinger, G Zugmaier, +3 authors, A von Stackelberg.
Leukemia, 2010 Oct 15; 25(1). PMID: 20944674
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.
Luca Gattinoni, Xiao-Song Zhong, +10 authors, Nicholas P Restifo.
Nat Med, 2009 Jun 16; 15(7). PMID: 19525962    Free PMC article.
Highly Cited.
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
P McLaughlin, A J Grillo-López, +13 authors, B K Dallaire.
J Clin Oncol, 1998 Aug 15; 16(8). PMID: 9704735
Highly Cited.
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.
S A Quezada, K S Peggs.
Br J Cancer, 2013 Mar 21; 108(8). PMID: 23511566    Free PMC article.
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
H J Kolb, J Mittermüller, +5 authors, W Wilmanns.
Blood, 1990 Dec 15; 76(12). PMID: 2265242
Highly Cited.
Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.
Daniel J Powell, Linda L Parker, Steven A Rosenberg.
J Immunother, 2005 Jul 08; 28(4). PMID: 16000960    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Mark P Rubinstein, Colleen A Cloud, +7 authors, David J Cole.
J Am Coll Surg, 2012 Mar 01; 214(4). PMID: 22360982    Free PMC article.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Evan J Lipson, Charles G Drake.
Clin Cancer Res, 2011 Sep 09; 17(22). PMID: 21900389    Free PMC article.
Highly Cited. Review.
Immunotherapy and chemotherapy--a practical partnership.
Richard A Lake, Bruce W S Robinson.
Nat Rev Cancer, 2005 May 03; 5(5). PMID: 15864281
Highly Cited. Review.
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
E A Walter, P D Greenberg, +4 authors, S R Riddell.
N Engl J Med, 1995 Oct 19; 333(16). PMID: 7675046
Highly Cited.
CAR T cells: driving the road from the laboratory to the clinic.
Eleanor J Cheadle, Hannah Gornall, +3 authors, David E Gilham.
Immunol Rev, 2013 Dec 18; 257(1). PMID: 24329792
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
M Mack, G Riethmüller, P Kufer.
Proc Natl Acad Sci U S A, 1995 Jul 18; 92(15). PMID: 7624362    Free PMC article.
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
Chrystal M Paulos, Claudia Wrzesinski, +11 authors, Nicholas P Restifo.
J Clin Invest, 2007 Jul 28; 117(8). PMID: 17657310    Free PMC article.
Highly Cited.
When cancer and immunology meet.
Martin Carroll.
Immunol Rev, 2014 Dec 17; 263(1). PMID: 25510267    Free PMC article.
Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.
Josep-Maria Ribera, Albert Ferrer, Jordi Ribera, Eulàlia Genescà.
Onco Targets Ther, 2015 Jul 15; 8. PMID: 26170691    Free PMC article.
IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.
K Andrijauskaite, S Suriano, +11 authors, M P Rubinstein.
Cancer Gene Ther, 2015 Jul 18; 22(7). PMID: 26182912    Free PMC article.
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
Kinga Majchrzak, Michelle H Nelson, +5 authors, Chrystal M Paulos.
Cancer Immunol Immunother, 2016 Jan 31; 65(3). PMID: 26825102    Free PMC article.
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
Alfredo Perales-Puchalt, Nikolaos Svoronos, +13 authors, Jose R Conejo-Garcia.
Clin Cancer Res, 2016 Jul 21; 23(2). PMID: 27435394    Free PMC article.
Immune Regulation of the Metastatic Process: Implications for Therapy.
A de Mingo Pulido, B Ruffell.
Adv Cancer Res, 2016 Sep 11; 132. PMID: 27613132    Free PMC article.
Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.
Arathi Kizhedath, Simon Wilkinson, Jarka Glassey.
Arch Toxicol, 2016 Oct 22; 91(4). PMID: 27766364    Free PMC article.
Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues.
Gene Kurosawa, Mototaka Sugiura, +2 authors, Yoshikazu Kurosawa.
Int J Mol Sci, 2016 Nov 12; 17(11). PMID: 27834817    Free PMC article.
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.
David A Braun, Catherine J Wu.
Cancer J, 2017 Apr 15; 23(2). PMID: 28410299    Free PMC article.
Bone Marrow Homing and Engraftment Defects of Human Hematopoietic Stem and Progenitor Cells.
Giovanni Caocci, Marianna Greco, Giorgio La Nasa.
Mediterr J Hematol Infect Dis, 2017 May 18; 9(1). PMID: 28512561    Free PMC article.
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.
Ping-Pin Zheng, Jin Li, Johan M Kros.
Med Res Rev, 2017 Sep 02; 38(1). PMID: 28862319    Free PMC article.
IL-2 and Beyond in Cancer Immunotherapy.
John M Wrangle, Alicia Patterson, +7 authors, Mark P Rubinstein.
J Interferon Cytokine Res, 2018 Feb 15; 38(2). PMID: 29443657    Free PMC article.
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
Hannah M Knochelmann, Aubrey S Smith, +3 authors, Chrystal M Paulos.
Front Immunol, 2018 Aug 25; 9. PMID: 30140266    Free PMC article.
Highly Cited. Review.
Advances in Engineering Cells for Cancer Immunotherapy.
Xiao Xu, Teng Li, +4 authors, Ran Mo.
Theranostics, 2019 Nov 07; 9(25). PMID: 31695806    Free PMC article.
Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.
M S Lim, Thomas Beyer, +25 authors, M Hacker.
Mol Imaging Biol, 2019 May 03; 22(1). PMID: 31049831
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Melanie Märklin, Ilona Hagelstein, +6 authors, Helmut R Salih.
J Immunother Cancer, 2019 May 31; 7(1). PMID: 31142382    Free PMC article.
Roles of follicle stimulating hormone and its receptor in human metabolic diseases and cancer.
Di Sun, Mingzhu Bai, +4 authors, Zhenbo Zhang.
Am J Transl Res, 2020 Aug 11; 12(7). PMID: 32774689    Free PMC article.
Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies.
Massimo Giuliani, Alessandro Poggi.
Cells, 2020 Jul 03; 9(7). PMID: 32610578    Free PMC article.
Toward a Better Understanding of Bioassays for the Development of Biopharmaceuticals by Exploring the Structure-Antibody-Dependent Cellular Cytotoxicity Relationship in Human Primary Cells.
Sébastien Wieckowski, Cécile Avenal, +2 authors, Florian Cymer.
Front Immunol, 2020 Nov 17; 11. PMID: 33193318    Free PMC article.
A T cell redirection platform for co-targeting dual antigens on solid tumors.
Leonie Enderle, Karim H Shalaby, +7 authors, Sachdev S Sidhu.
MAbs, 2021 Jul 01; 13(1). PMID: 34190031    Free PMC article.
Haematological malignancies implications during the times of the COVID-19 pandemic.
Eleni Papakonstantinou, Konstantina Dragoumani, +6 authors, Dimitrios Vlachakis.
Oncol Lett, 2021 Nov 16; 22(6). PMID: 34777590    Free PMC article.